| Name | Title | Contact Details |
|---|
Marian Health System is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is dedicated to the systematic development of personalized, highly-selective cancer therapies that target the molecular aberrations that cause cancer and the patients most likely to benefit. We are looking for talented, innovative thinkers who share our passion and dedication to patients and want to be at the forefront of exciting developments in the treatment of cancer.
ICU Medical, Inc. is engaged in the development, manufacture and sale of disposable medical connection systems for use in vascular therapy applications.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Pacific Nano Technology div Agilent is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.